Moderna(MRNA.O)上涨3.8%，此前其新冠疫苗获得美国食品药品监督管理局（FDA）对6个月至11岁儿童的全面批准。

Core Viewpoint - Moderna's stock increased by 3.8% following the full approval of its COVID-19 vaccine by the U.S. Food and Drug Administration (FDA) for children aged 6 months to 11 years [1] Company Summary - Moderna received comprehensive approval from the FDA for its COVID-19 vaccine for the pediatric age group of 6 months to 11 years [1] Industry Summary - The approval signifies a significant milestone in the vaccination efforts against COVID-19, particularly for younger populations, potentially impacting public health strategies and vaccine uptake [1]